FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
632 letters match. Newest first.
-
DrugsAromas Para El Alma S.A.
Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.
High risk -
DrugsEnviroServe Chemicals & Cleaners Ltd.
EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.
High risk -
DrugsGreco Gas, Inc.
Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.
High risk -
DrugsTJA Health, LLC
FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.
High risk -
DrugsAvaria Health & Beauty Corp.
FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.
High risk -
DrugsZydus Lifesciences Limited
FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.
High risk -
DrugsOrean Personal Care Ltd.
FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.
High risk -
DrugsRegenerative Processing Plant, LLC
FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.
High risk -
DrugsKaylaan LLC
FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.
High risk -
DrugsAnuMed International, LLC
FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.
High risk -
DrugsCARsgen Therapeutics Corporation
FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.
High risk -
DrugsEyePoint Pharmaceuticals, Inc.
FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.
High risk -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
DrugsIntercos Europe S.p.A
FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.
High risk -
DrugsLS Promotions Inc.
LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.
High risk -
DrugsNowrez & Ismail Shukri Company
FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.
High risk -
DrugsGuangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.
FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.
High risk -
DrugsOmega Tech Labs LLC
Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.
High risk -
DrugsVelocity Pharma LLC
Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.
High risk -
DrugsBrassica Pharma Pvt. Ltd.
FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.
High risk -
DrugsGenuine Virgin Aloe Corp dba Triderma
FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.
High risk -
DrugsYahon Enterprise Co., Ltd.
FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.
High risk -
DrugsJiangsu Hengrui Pharmaceuticals Co., Ltd.
FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.
High risk -
DrugsYangZhou SuXiang Medical Instrument Co., Ltd.
FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.
High risk -
DrugsMax Chemical Inc.
FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.
High risk -
DrugsARG Laboratories, Inc.
FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.
High risk -
DrugsArt of Beauty Company, Inc.
FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.
High risk -
DrugsreBom Co., Ltd.
reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.
High risk -
DrugsOptikem International Inc.
FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.
High risk -
DrugsLaboratorio Magnachem International
FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.
High risk -
DrugsSun Pharmaceutical Industries Limited
FDA cited Sun Pharmaceutical Industries for inadequate cleaning and maintenance at its Dadra drug plant, risking cross-contamination, and for weak investigations.
High risk -
DrugsSani-Care Salon Products, Inc.
FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.
High risk -
DrugsGFA Production Xiamen Co., Ltd.
GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.
High risk -
DrugsLandy International
FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.
High risk -
DrugsAqualex Co., Ltd.
Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.
High risk -
DrugsTCT Nutraceuticals SDN. BHD
FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.
High risk -
DrugsFancystage Unipessoal, LDA
FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.
High risk -
DrugsCosmetic Solutions, LLC
FDA warns Cosmetic Solutions over manufacturing failures and unapproved OTC drugs at Boca Raton plant.
High risk -
DrugsAruba Aloe Balm N.V.
Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.
High risk -
DrugsBiomic Sciences, LLC dba ION Intelligence of Nature
Biomic Sciences' nasal spray was grossly contaminated with microorganisms, and FDA also found manufacturing and labeling violations.
High risk -
DrugsSafari Stem Cell, LLC
FDA warned Safari Stem Cell for selling unapproved stem cell animal drugs made without required CGMP controls, including sterility testing.
High risk -
DrugsSeatex, LLC
FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warned sterile drug compounder Central Admixture Pharmacy Services (Phoenix) that dirty areas and weak sterility testing made its drugs adulterated.
High risk -
DrugsNatuzen Co., Ltd.
Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.
High risk -
DrugsGrupo Quimico SRL
FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.
High risk -
DrugsWestwood Laboratories LLC
FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.
High risk -
DrugsCohere Beauty
FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.
Medium -
DrugsSeatex, LLC
Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warned Central Admixture Pharmacy Services' Allentown outsourcing facility over sterile drug contamination and CGMP failures.
High risk